EUCTR2017-005121-21-DE进行中（未招募）1 期
Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib
niversitätsklinikum Essen0 个研究点目标入组 20 人开始时间: 2018年9月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of informed consent prior to any study specific procedures
- •2. Patients (male/female) must be > 18 years of age.
- •3. EGFRmutated NSCLC not amenable to curative treatment (surgery, curative radiochemotherapy).
- •4. Acquired resistance to a first- or second-generation EGFR-TKI (e.g. afatinib, erlotinib, gefitinib) following initial benefit (defined as objective response, or stable disease for at least 3 months)
- •5. No tumor rebiopsy available or negative result for EGFR T790M mutation status by a SoC molecular pathology test (e.g. Sanger sequencing, PCR-based genotyping, deep sequencing) of a rebiopsy of a progressive tumor lesion
- •6. Negative finding from EGFR T790M mutation testing in plasma-derived DNA using a SoC assay (e.g. Roche Cobas)
- •7. At least one tumor lesion with significant FDG uptake as determined by PET/CT scanning prior to study treatment
- •8. Consent to the research use of donated biological samples.
- •9. World Health Organization (WHO) performance status 0-2.
- •10. Patients must have a life expectancy = 12 weeks.
- •11. Females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, which will be repeated on a monthly Basis, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening:
- •* Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments
- •* Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with LH and FSH levels in the post-menopausal range for the institution
- •* Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
- •12. Male patients should be willing to use barrier contraception (see Restrictions, Section 3.6).
- •13. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.EGFR-mutated NSCLC and demonstration of the T790M resistance mutation by standard assay technology in tumor-derived or plasma-derived DNA
- •2.Absence of a tumor lesion with significant FDG uptake at PET/CT scanning prior to study treatment
- •3.Involvement in the planning and/or conduct of the study (applies to both sponsor staff and/or staff at the study site)
- •4.Previous treatment with osimertinib or any experimental or approved mutation-specific EGFR-TKI with clinical activity against the EGFR T790M resistance mutation
- •5.Treatment with an investigational drug within one week or five drug half-lives (whichever is longer) of the compound (3 weeks for antibodies)
- •6.Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 week prior) (Appendix A - Guidance regarding Potential Interactions With Concomitant Medications). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4. A list for drug interaction potential is found in section 5.1.6.4 of the osimertinib IB.
- •7.Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior chemotherapy related neuropathy.
- •8.Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator’s opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
- •9.Patients with symptomatic CNS metastases who are neurologically unstable
- •10.Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
- •11.Fasting blood glucose levels above 150 mg/dl (precluding informative FDG-PET/CT scanning)
- •12.Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
- •Absolute neutrophil count <1.5 x 109/L
- •Platelet count <100 x 109/L
- •Haemoglobin <90 g/L
- •Alanine aminotransferase >2.5 times the upper limit of normal (ULN) if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
- •Aspartate aminotransferase >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
- •Total bilirubin >1.5 times ULN if no liver metastases or >3 times ULN in the presence of documented Gilbert’s Syndrome (unconjugated hyperbilirubinaemia) or liver metastases
- •Creatinine >1.5 times ULN concurrent with creatinine clearance <50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
- •13.Any of the following cardiac criteria:
- •a.Mean resting corrected QT interval (QTc using Fredericia’s formula) > 470 msec obtained from the screening clinic ECG machine-derived QTc value
- •b.Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
- •c.Any factors tha
研究者
相似试验
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54
已完成
不适用
An Evaluation of tumor response to osimertinib by early FDG-PET finding in patients with T790M positive EGFR mutated non-small cell lung cancerT790M (detected by cobas EGFR Mutation Test v2) from the relapsed tumor after EGFR-TKI therapy.JPRN-UMIN000027550Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, 3-1-1, Asahi Matsumoto, 390-8621, Japan,30
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
进行中（未招募）
1 期
Study to osimertinib treatment in patients with lung cancer.on-small cell lung carcinomaEUCTR2018-004290-28-NL20
已完成
不适用
Pharmacokinetic boosting of osimertinib in patients with non-small cell lung cancer.lung cancerNL-OMON55742Medisch Universitair Ziekenhuis Maastricht29